Patents by Inventor Birte Nolting

Birte Nolting has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12263228
    Abstract: Provided herein are lipids having the Formula I or Formula Ia: and pharmaceutically acceptable salts thereof, wherein R?, R1, R2, R3, R4, R5, R6a, R6b, X1, X2, and n are as defined herein for Formula I and Formula Ia, respectively. Also provided herein are lipid nanoparticle (LNP) compositions comprising lipid having the Formula I or Ia and a capsid-free, non-viral vector (e.g., ceDNA). In one aspect of any of the aspects or embodiments herein, these LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).
    Type: Grant
    Filed: March 21, 2024
    Date of Patent: April 1, 2025
    Assignee: Generation Bio Co.
    Inventors: Matthew G. Stanton, Birte Nolting, Andrew Milstead
  • Patent number: 12252470
    Abstract: Provided herein are lipids having the Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, a, and b are as defined herein. Also provided herein are lipid nanoparticle (LNP) compositions comprising lipid having the Formula (I) and a capsid-free, non-viral vector (e.g., ceDNA). In one aspect of any of the aspects or embodiments herein, these LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).
    Type: Grant
    Filed: April 24, 2024
    Date of Patent: March 18, 2025
    Assignee: Generation Bio Co.
    Inventors: Matthew G. Stanton, Birte Nolting
  • Publication number: 20240382432
    Abstract: Provided herein are pharmaceutical compositions comprising a lipid nanoparticle (LNP) and a therapeutic nucleic acid (TNA), wherein the LNP comprises a single-chain variable fragment (scFv) linked to the LNP, and at least one pharmaceutically acceptable excipient. The scFv is capable of binding an antigen present on the surface of a cell, advantageously providing LNP compositions that target only those cells or tissues expressing the receptor.
    Type: Application
    Filed: July 13, 2022
    Publication date: November 21, 2024
    Inventors: Phillip Samayoa, Nathaniel Silver, Prudence Yui Tung Li, Randall Newton Toy, Birte Nolting, Lalita Oonthonpan
  • Publication number: 20240299580
    Abstract: Provided herein are pharmaceutical compositions comprising a lipid nanoparticle (LNP) and a therapeutic nucleic acid (TNA), wherein the LNP comprises an ApoE polypeptide, or a fragment thereof and/or an ApoB polypeptide, or a fragment thereof, linked to the LNP, and at least one pharmaceutically acceptable excipient. The ApoE polypeptide, or the fragment thereof, and/or the ApoB polypeptide, or the fragment thereof, are capable of binding a low-density lipoprotein (LDL) receptor, or LDL receptor family member, advantageously providing LNP compositions that can be directed to any cell or tissue expressing the LDL receptor.
    Type: Application
    Filed: June 7, 2022
    Publication date: September 12, 2024
    Inventors: Michelle LeBlanc, Gregory Feinstein, Randall Newton Toy, Birte Nolting, Nathaniel Silver, Phillip Samayoa, Jon Edward Chatterton, Matthew Manganiello, Douglas A. Rose, Ryan M. Delaney
  • Publication number: 20240294474
    Abstract: Provided herein are lipids having the Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, a, and b are as defined herein. Also provided herein are lipid nanoparticle (LNP) compositions comprising lipid having the Formula (I) and a capsid-free, non-viral vector (e.g., ceDNA). In one aspect of any of the aspects or embodiments herein, these LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).
    Type: Application
    Filed: April 24, 2024
    Publication date: September 5, 2024
    Inventors: Matthew G. Stanton, Birte Nolting
  • Publication number: 20240293574
    Abstract: Provided herein are cationic lipids having the Formula I or la: and pharmaceutically acceptable salts thereof, wherein R?, R1, R2, R3, R4, R5, R6a, R6b, X, and n are as defined herein. Also provided herein are lipid nanoparticle (LNP) compositions comprising a cationic lipid having the Formula I or la and a capsid-free, non-viral vector (e.g., ceDNA). In one aspect of any of the aspects or embodiments herein, these LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).
    Type: Application
    Filed: June 14, 2022
    Publication date: September 5, 2024
    Inventors: Matthew G. Stanton, Birte Nolting, Andrew Milstead
  • Publication number: 20240285796
    Abstract: Provided herein are lipids having the Formula I or Formula Ia: and pharmaceutically acceptable salts thereof, wherein R?, R1, R2, R3, R4, R5, R6a, R6b, X1, X2, and n are as defined herein for Formula I and Formula Ia, respectively. Also provided herein are lipid nanoparticle (LNP) compositions comprising lipid having the Formula I or Ia and a capsid-free, non-viral vector (e.g., ceDNA). In one aspect of any of the aspects or embodiments herein, these LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).
    Type: Application
    Filed: March 21, 2024
    Publication date: August 29, 2024
    Inventors: Matthew G. Stanton, Birte Nolting, Andrew Milstead
  • Publication number: 20240226325
    Abstract: Provided herein are lipids having the Formula I or Formula la, and pharmaceutically acceptable salts thereof, wherein R?, R1, R2, R3, R4, R5, R6a, R6b, X1, X2, and n are as defined herein for Formula I and Formula la, respectively. Also provided herein are lipid nanoparticle (LNP) compositions comprising lipid having the Formula I or la and a capsid-free, non-viral vector (e.g., ceDNA). In one aspect of any of the aspects or embodiments herein, these LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).
    Type: Application
    Filed: April 20, 2022
    Publication date: July 11, 2024
    Inventors: Matthew G. Stanton, Birte Nolting, Andrew Milstead
  • Publication number: 20230181764
    Abstract: Provided herein are lipids having the Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R1?, R2, R2?, R3, R3?, R4, R4?, R5, and R5?, are as defined herein. Also provided herein are lipid nano article (LNP) compositions comprising lipid having the Formula (I) and a capsid-free, non-viral vector (e.g., ceDNA). In one aspect, these LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).
    Type: Application
    Filed: May 17, 2021
    Publication date: June 15, 2023
    Inventors: Matthew G. Stanton, Birte Nolting
  • Publication number: 20230159459
    Abstract: Provided herein are lipids having the Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, a, and b are as defined herein. Also provided herein are lipid nanoparticle (LNP) compositions comprising lipid having the Formula (I) and a capsid-free, non-viral vector (e.g., ceDNA). In one aspect of any of the aspects or embodiments herein, these LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).
    Type: Application
    Filed: March 26, 2021
    Publication date: May 25, 2023
    Inventors: Matthew G. Stanton, Birte Nolting
  • Publication number: 20220370357
    Abstract: Provided herein are ionizable lipids represented by the Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R1?, R2?, R3?, R4?, R5?, R6?, m, and n are as defined herein. Also provided herein are lipid nanoparticle (LNP) compositions comprising an ionizable lipid of the invention and a capsid-free, non-viral vector (e.g., ceDNA). These LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).
    Type: Application
    Filed: November 23, 2020
    Publication date: November 24, 2022
    Inventors: Matthew G. Stanton, Birte Nolting, Gregory Feinstein, Michelle LeBlanc, Jon Edward Chatterton